Bone Biologics Corp

Bone Biologics Corp

Bone Biologics Corp was founded in 2004 and operates as a clinical-stage medical device company headquartered in Burlington, Massachusetts. Jeffrey Frelick serves as President and Chief Executive Officer, steering a lean organization that focuses entirely on advancing Nell-1, a recombinant human protein intended to stimulate bone growth as an alternative to autograft procedures. The company's public-company structure, with shares trading on the Nasdaq Capital Market, provides its primary access to growth funding — a capital pathway markedly different from the venture-funded private orthobiologics startups that have historically dominated this niche. The firm's strategy hinges on a single platform: a recombinant Nell-1 protein delivered via a demineralized bone matrix carrier. This asset is designed for spinal fusion procedures, a market segment that was valued at approximately $7.5 billion globally in 2023 (per Grand View Research, 2024). Bone Biologics does not maintain a diversified pipeline of implantable materials like major orthopedics competitors; instead, its deployment is binary — all resources flow toward preclinical and eventual clinical validation of Nell-1 in posterolateral spinal fusion. The geographic footprint is concentrated in the United States, where the company engages with FDA regulatory pathways and academic research institutions to advance its technology. Total headcount remains small and undisclosed, consistent with a company that had approximately $3 million in cash and cash equivalents as of the first quarter of 2024 (per the firm's SEC filings, 2024). February 2024: Bone Biologics executed a 1-for-30 reverse stock split to maintain Nasdaq listing compliance, a regulatory maneuver that signals the intense cash-conservation posture of a pre-revenue company. The company maintains a single headquarters in Burlington, Massachusetts, and does not operate adjacent philanthropic vehicles, real-asset arms, or co-investor clubs — the architecture has no room for diversions from the core Nell-1 program. What genuinely separates Bone Biologics from larger orthobiologics companies is its commitment to a single-molecule thesis in a field where competitors typically hedge across ceramics, allograft tissues, and synthetic polymers. This purity of pipeline — one protein, one indication pathway, one regulatory destination — creates a binary outcome profile that is uncommon even among small-cap biotech peers. The company's Nasdaq listing also subjects it to quarterly disclosure obligations, giving any institutional allocator who considers public micro-cap healthcare positions a transparent, if volatile, window into a concentrated orthobiologics bet.